FindTrial
Sign In

Randomised comparison of cyclical anthracyline-based chemotherapy [PA(B1)OE] with alternating chemotherapy [Ch1VPP/PABLOE] in advanced Hodgkin's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63499520
Enrollment
Unknown
Registered
2001-07-01
Start date
1990-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (Hodgkin's) Cancer Lymphoma (Hodgkin's)

Interventions

FIRST RANDOMISATION: Patients are randomised to one of two chemotherapy regimens: 1. PA(B1)OE Regimen: Multi-drug chemotherapy with adriamycin, vincristine, prednisolone, etoposide and bleomycin (PA(

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Previously untreated and properly stage patients with Hodgkin's disease for whom chemotherapy is indicated, ie stage I and IIA (poor prognosis), IB, IIB, III and IV 2. Patients must be free from any irreversible medical condition that would drastically limit their life span or prohibit use of combination chemotherapy 3. Aged 15 to 69 years inclusive

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026